PTAB Holds Indian Tribes Don’t Offer an Out from IPR

by Patterson Belknap Webb & Tyler LLP
Contact

In a highly anticipated decision on the Saint Regis Mohawk Tribe’s motion to terminate inter partes review proceedings, the Patent Trial and Appeal Board rejected tribal sovereign immunity to IPRs.  The PTAB’s decision also raised doubts about the effectiveness of assignments even in cases where the sovereign assignee has immunity but the assignor effectively still owns the patent.  The portion of the decision broadly holding that tribal sovereign immunity does not apply to IPRs came as a surprise to some commentators, who observed that the PTAB could have reached the same result on narrower grounds.  Following on the heels of the PTAB’s December 2017 University of Minnesota decision holding that a sovereign waives immunity to IPRs when it asserts the patent at issue in district court, Saint Regis Mohawk Tribe deals another blow for patentees seeking to avoid IPRs with sovereign immunity.

Background

The dispute began in 2015, when Allergan asserted various patents covering its dry-eye treatment, Restasis, against Mylan and other generic manufacturers in the Eastern District of Texas.  Restasis is a blockbuster product for Allergan, bringing in over $1.4 billion of U.S. sales revenue in 2016.  After being sued for infringement of the Restasis patents, the generics filed IPRs challenging the patents at the PTAB. 

To try to avoid the IPRs on the basis of sovereign immunity, in September 2017, Allergan assigned the Restasis patents to the Saint Regis Mohawk Tribe, and took an exclusive license back from the Tribe.  The Tribe received a $13.5 million upfront payment upon execution of the agreement, and is eligible to receive $15 million in annual royalties.  Following this assignment-and-license-back transaction, the Tribe joined the pending district court proceedings as a party plaintiff.  Shortly after the Tribe joined the action, the Texas district court found the Restasis patents invalid.  In the opinion, Judge William Bryson also noted that he “ha[d] serious concerns about the legitimacy of the tactic that Allergan and the Tribe have employed.”

Meanwhile, the Tribe had also filed a motion to terminate the pending IPR proceedings following the September 2017 assignment of the Restasis patents, arguing that the Tribe, as the new patent owner, enjoyed sovereign immunity from review.

The PTAB Decision

The PTAB denied the Tribe’s motion to terminate proceedings in a decision rejecting tribal sovereign immunity as a bar to IPRs.  The Board found that there was no controlling precedent or statutory basis for the application of tribal sovereign immunity in IPR proceedings.  The PTAB first rejected the idea that precedent providing state sovereign immunity to PTAB reviews extends to tribal sovereign immunity.  The PTAB then held that IPR proceedings are not the type of private “suit” to which an Indian tribe would traditionally enjoy immunity under the common law. 

Even assuming for the sake of argument that the Tribe were entitled to assert immunity, the PTAB held, the proceedings could continue with Allergan’s participation as the “patent owner.”  As the decision explained, the “party that has been granted all substantial rights under the patent is considered the owner regardless of how the parties characterize the transaction that conveyed those rights.”  If the licensor transfers “all substantial rights” in the patent, the exclusive license is “tantamount to an assignment,” and the licensee is effectively the patent owner.

Applying this framework, the PTAB concluded that the exclusive license the Tribe granted back to Allergan was tantamount to an assignment, pointing to a variety of factors.  Here, the license gave Allergan primary control over the right to enforce the patents, while the Tribe retained only “an illusory or superficial right to sue for infringement.”  Allergan also retained the exclusive right to use the patents for all FDA-approved uses, while the Tribe’s “own right to practice and license the challenged patents is significantly limited.”  The license also provided Allergan other substantial rights, including the right to sublicense, reversionary rights, rights to litigation and licensing proceeds, the right to defend and control prosecution in PTO proceedings, and the right to assign its interest.  Despite the parties’ characterization of their transaction as a license, the PTAB concluded that Allergan remained the effective patent owner.  Thus, the Board held that the IPR proceedings “may continue with Allergan as the patent owner, and that the Tribe is not an indispensable party to these proceedings.”

Immunity-Driven Assignments to Sovereigns following St. Regis Mohawk Tribe

With Saint Regis Mohawk Tribe and the PTAB’s recent decision in University of Minnesota, immunity-driven assignments to Indian tribes or state sovereigns are likely to be on the wane.

Since the PTAB found that the Saint Regis Mohawk Tribe could not assert sovereign immunity to IPRs in the first instance, it did not reach its recent University of Minnesota holding that a sovereign waives immunity to IRPs by asserting the patent at issue in federal court.  This narrower ground of waiver would have been another reason to reject the Tribe’s claim to sovereign immunity.  The patents at issue were already being asserted in district court and the Tribe had joined Allergan’s district court actions as a party plaintiff after entering into the assignment-and-license-back transaction with Allergan.  Indeed, as the Board explains in University of Minnesota based on Supreme Court precedent, allowing a sovereign to “selectively” assert sovereign immunity in an IPR while asserting the same patent in court “would result in substantial unfairness and inconsistency.”

Further, the PTAB’s analysis of effective patent ownership has significant implications not just for Indian tribes, but for state sovereigns and their commercial partners as well.  The Board’s finding that the Tribe’s exclusive license back to Allergan was tantamount to an assignment, making Allergan the effective patent owner, applies with equal force to immunity-driven assignments to state sovereigns.  According the PTAB, assignments that provide a sovereign with only illusory or superficial rights do not provide a bar to IPR.

With Indian tribes unable to claim sovereign immunity to IRPs, a sovereign’s assertion of a patent in district court being a waiver, and illusory assignments ineffective to shield patents from IPRs, immunity-driven patent assignments are unlikely to be pursued going forward.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP
Contact
more
less

Patterson Belknap Webb & Tyler LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.